ClinicalTrials.gg
Not yet recruitingNCT07682792GEMSTONEUpdated Nov 5, 2026

Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia

A Phase 2 interventional study of Golidocitinib in Mycosis Fungoides/Sezary Syndrome and T-cell Large Granular Lymphocytic Leukemia, sponsored by Washington University School of Medicine. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Treatment

How we know

Updated Nov 5, 2026Start date movedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 360 studies in Mycosis Fungoides with a site in United States — 24 open to participants now, 36 under way, none of them phase 3. Mycosis Fungoides · United States.

Planned enrollment
167th of 279
24 · median 32
Started
2026
with 2 others
Phase 2
101 of 360
8 open now
Primary completion
2030-04
later than 30 of 35 live
Registered
358th of 360
by date

Among the 360 studies in Mycosis Fungoides with a site in United States, this one is the 167th largest by planned enrollment of the 279 interventional ones that give a count, is one of 3 that started in 2026, is one of 101 in phase 2, reaches primary completion later than 30 of the 35 other live ones, and was the 358th registered.

Mycosis Fungoides

447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.

Browse Mycosis Fungoides studies →

Open to participants now

24 of the 360 studies in Mycosis Fungoides with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Mycosis Fungoides studies recruiting now, 25 (83%) set no upper age limit and 1 (3%) stops at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 360 studies in Mycosis Fungoides with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, single-institution pilot study of single-agent golidocitinib enrolling up to 24 patients in two cohorts: a) advanced-stage mycosis fungoides/Sézary syndrome (MF/SS), n=12, or b) T-cell large granular lymphocytic leukemia (T-LGLL) requiring treatment, n=12. Patients will receive single agent golidocitinib at the previously established dose of 150 mg QD as determined in the phase I and II studies of golidocitinib.

03

Conditions studied

  • Mycosis Fungoides/Sezary Syndrome
  • T-cell Large Granular Lymphocytic Leukemia

Keywords

  • JAK inhibitor
  • Golidocitinib
  • Cutaneous T-cell lymphoma
04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for MF/SS:

  • or cytologically confirmed mycosis fungoides or Sézary syndrome, stages IB to IVB with and/or detectable blood involvement based on the Global Response Criteria for CTCL (Olsen et al., 2022).
  • Received at least one .
  • Requires systemic therapy for their CTCL, in the opinion of the treating physician.
  • At least 18 years of age.
  • performance status ≤ 2
  • Adequate counts and organ function as defined below:

    • count > 75 K/cumm, unless related to lymphoma, in which case platelet count must be > 50 K/cumm. Platelet transfusion may be utilized to meet inclusion criteria, as long as the platelet count remains at the above threshold without transfusion for 5 days.
    • Estimated (as calculated by the method) or measured creatinine clearance ≥ 30 mL/min.
    • Serum total ≤ 1.5 x IULN if no liver involvement, or ≤ 2 x IULN in the presence of Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver involvement.
    • (AST) and alanine aminotransferase (ALT) ≤ 2.5 x IULN, or ≤ 5 x IULN if documented hepatic involvement with lymphoma.
  • Able to swallow pills.
  • The effects of golidocitinib on the developing human fetus are unknown. For this reason, women of and men must agree to use highly effective methods of for the duration of study participation and for 3 months after the last dose of golidocitinib for female patients and female partners of male patients, or for 6 months after the last dose of golidocitinib for male patients and male partners of female patients. Should a woman become pregnant or suspect she is pregnant or a male patient suspect he has impregnated another while participating in this study, s/he must inform the treating physician immediately.
  • Ability to understand and willingness to sign an IRB approved written document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Inclusion Criteria for LGLL

  • Diagnosis of T-LGLL defined as: CD3+CD8+ cell population > 650/mm3 or CD3+CD8+CD57+ population > 500/mm3 and the presence of a clonal T-cell receptor (within 1 month of diagnosis).

Note: patients with MDS-like T-LGLL may be included with PI approval even if CD3+CD8+ cell population is \< 650/mm3, though +TCR is required. Natural-Killer (NK) LGL is also permitted, provided there is a clonal NK-cell population noted with > 500 cells/mm3.

  • Had at least one line of systemic therapy for T-LGLL.
  • Require treatment for T-LGLL, as defined by meeting one or more of the below criteria:

    • Symptomatic anemia with \< 10 g/dL
    • Transfusion-dependent anemia
    • Neutropenia with (ANC) \< 0.5 K/cumm
    • Neutropenia with ANC \< 1.5 K/cumm with recurrent infections
  • At least 18 years of age.
  • ECOG performance status ≤ 2
  • Adequate counts and organ function as defined below:

    • Platelet count > 50 K/cumm. Platelet transfusion may be utilized to meet inclusion criteria, as long as the platelet count remains > 50 K/cumm within 5 days of last transfusion.
    • Estimated (as calculated by the Cockcroft-Gault method) or measured creatinine clearance ≥ 30 mL/min.
    • Serum total bilirubin ≤ 1.5 x IULN if no liver involvement, or ≤ 2 x IULN in the presence of Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver involvement.
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x IULN, or ≤ 5 x IULN if documented hepatic involvement with T-LGLL.
  • Patients with treated are eligible if follow-up brain imaging after CNS-directed therapy shows no evidence of progression.
  • Able to swallow pills.
  • The effects of golidocitinib on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use highly effective methods of contraception for the duration of study participation and for 3 months after the last dose of golidocitinib for female patients and female partners of male patients, or for 6 months after the last dose of golidocitinib for male patients and male partners of female patients. Should a woman become pregnant or suspect she is pregnant or a male patient suspect he has impregnated another while participating in this study, s/he must inform the treating physician immediately.
  • Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion Criteria for MF/SS:

  • Active CNS lymphoma.
  • A history of other , with the exception of prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial.
  • Currently receiving any other investigational agents.
  • Concomitant use of another systemic therapy for MF/SS. Patients must have the following minimum from previous treatments:

    • At least 8 weeks for low-dose (12 Gy or less) total skin electron beam therapy (TSEBT).
    • At least 4 weeks for systemic cytotoxic anticancer agents or for tumor-targeting monoclonal antibodies (mAbs), with the exception of alemtuzumab, for which the washout is at least 16 weeks.
    • At least 2 weeks or 5 half-lives (whichever is shorter) for systemic retinoids, interferons, vorinostat, romidepsin, and denileukin diftitox, or anticancer investigational agents that are not defined as immunotherapy.
    • At least 1 week for topical retinoids, nitrogen mustard, or imiquimod.
  • Receipt of medications or herbal supplements known to be strong inhibitors of within the following time frames prior to the first dose of golidocitinib:

    • 7 days for Ketoconazole, itraconazole, indinavir, saquinovir, nelfinavir, atazanavir, amprenavir, fosamprenavir, troleandomycin, telithromycin, fluconazole, nefazodone, cimetidine, aprepitant, miconazole, fluvoxamine
    • 14 days for Erythromycin, clarithromycin, verapamil, ritonavir, diltiazem
    • 6 weeks for amiodarone
  • Receipt of medications known to prolong the within the following time frames:

    • 2 days for clarithromycin, droperidol, erythromycin, procainamide
    • 14 days for Cisapride, disopyramide, dofetilide, domperidone, ibutilide, quinidine, sotalol, sparfloxacin, thioridazine
    • 4 weeks for levomethadyl, methadone, pimozide
    • 6 weeks for arsenic trioxide
    • 8 weeks for pentamidine
    • 52 weeks for chloroquine
  • Gastrointestinal disorders, or any other condition that may significantly interfere with absorption of the study medication by the investigator's assessment.
  • Uncontrolled active infection requiring IV antibiotic, antiviral, or antifungal medications within 14 days before the first dose of study drug. Infections (e.g., urinary tract infection) controlled on concurrent antimicrobial agents and antimicrobial prophylaxis per institutional guidelines are acceptable.
  • Current known active or chronic infection with , , or . All patients will require serologic testing to be performed within 6 months prior to C1D1.

    • Patients with chronic HBV are defined as patients with positive hepatitis B serology: Patients with a negative HBsAg and a positive HBcAb require an undetectable/negative hepatitis B DNA test (e.g. polymerase chain reaction [PCR] test) to be enrolled and will require prophylactic antiviral treatment initiated prior to the first dose of study drug, and continued until approximately 6 to 12 months after completion of study drug(s).
    • Patients with chronic HCV infection are defined as patients with a positive hepatitis C antibody (anti-HCV) test:
    • Patients with a positive anti-HCV antibody test require a quantitative HCV RNA viral load test (e.g., polymerase chain reaction [PCR] test) to determine eligibility. Patients with a positive anti-HCV antibody and a detectable/positive HCV RNA (i.e., active chronic HCV infection) are not eligible.
    • Patients with a positive anti-HCV antibody and an undetectable/negative HCV RNA (i.e., prior resolved infection or previously treated and cured HCV) are eligible for enrollment without antiviral treatment.
  • Unstable or severe uncontrolled medical condition or any important medical or psychiatric illness or abnormal laboratory finding that would, in the investigator's judgment, increase the risk to the patient associated with his/her participation in this study.
  • QTcF ≥ 480 msec.
  • Pregnant and/or breastfeeding.
  • Concurrent immune-suppressive therapy exceeding prednisone 20 mg equivalent.

Exclusion Criteria for LGLL

  • Active CNS involvement with T-LGLL.
  • A history of other malignancy with the exception of prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
  • Currently receiving any other investigational agents, or receipt of another systemic therapy for T-LGLL within 14 days or 5 half-lives of the first dose of golidocitinib, whichever is shorter.
  • Receipt of medications or herbal supplements known to be strong inhibitors or inducers of CYP3A4 within the following time frames prior to the first dose of golidocitinib:

    • 7 days for Ketoconazole, itraconazole, indinavir, saquinovir, nelfinavir, atazanavir, amprenavir, fosamprenavir, troleandomycin, telithromycin, fluconazole, nefazodone, cimetidine, aprepitant, miconazole, fluvoxamine
    • 14 days for Erythromycin, clarithromycin, verapamil, ritonavir, diltiazem
    • 6 weeks for amiodarone
  • Receipt of medications known to prolong the QT interval within the following time frames:

    • 2 days for clarithromycin, droperidol, erythromycin, procainamide
    • 14 days for Cisapride, disopyramide, dofetilide, domperidone, ibutilide, quinidine, sotalol, sparfloxacin, thioridazine
    • 4 weeks for levomethadyl, methadone, pimozide
    • 6 weeks for arsenic trioxide
    • 8 weeks for pentamidine
    • 52 weeks for chloroquine
  • Gastrointestinal disorders, or any other condition that may significantly interfere with absorption of the study medication by the investigator's assessment.
  • Uncontrolled active infection requiring IV antibiotic, antiviral, or antifungal medications within 14 days before the first dose of study drug. Infections (e.g., urinary tract infection) controlled on concurrent antimicrobial agents and antimicrobial prophylaxis per institutional guidelines are acceptable.
  • Current known active or chronic infection with HIV, hepatitis B, or hepatitis C. All patients will require serologic testing to be performed within 6 months prior to C1D1.

    • Patients with chronic HBV are defined as patients with positive hepatitis B serology: Patients with a negative HBsAg and a positive HBcAb require an undetectable/negative hepatitis B DNA test (e.g. polymerase chain reaction [PCR] test) to be enrolled and will require prophylactic antiviral treatment initiated prior to the first dose of study drug, and continued until approximately 6 to 12 months after completion of study drug(s).
    • Patients with chronic HCV infection are defined as patients with a positive hepatitis C antibody (anti-HCV) test: Patients with a positive anti-HCV antibody test require a quantitative HCV RNA viral load test (e.g., polymerase chain reaction [PCR] test) to determine eligibility. Patients with a positive anti-HCV antibody and a detectable/positive HCV RNA (i.e., active chronic HCV infection) are not eligible. AND Patients with a positive anti-HCV antibody and an undetectable/negative HCV RNA (i.e., prior resolved infection or previously treated and cured HCV) are eligible for enrollment without antiviral treatment.
  • Unstable or severe uncontrolled medical condition or any important medical or psychiatric illness or abnormal laboratory finding that would, in the investigator's judgment, increase the risk to the patient associated with his/her participation in this study.
  • QTcF ≥ 480 msec.
  • Pregnant and/or breastfeeding.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Advanced-stage mycosis fungoides/Sézary syndrome (MF/SS) - Golidocitinib

    Patients with advanced-stage MF/SS will take golidocitinib as a 150 mg pill orally each day of a 28-day cycle.

    Drug: Golidocitinib

  • Experimental
    Cohort 2: T-cell large granular lymphocytic leukemia (T-LGLL) - Golidocitinib

    Patients with T-LGLL will take golidocitinib as a 150 mg pill orally each day of a 28-day cycle.

    Drug: Golidocitinib

Interventions

  • Golidocitinib is a JAK1 kinase inhibitor taken orally at a dose of 150mg.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the proportion of evaluable patients achieving complete response (CR) or partial response (PR). As assessed according to the Global Response Criteria for CTCL and and International Consensus Criteria for T-LGLL.

    Time frame: At four months after start of treatment

Secondary outcomes

  1. Best overall response rate

    Best overall response rate is defined by the best response of a given patient while being evaluated on study as assessed according to the Global Response Criteria for CTCL and and International Consensus Criteria for T-LGLL.

    Time frame: Through completion of treatment (estimated to be 12 months)

  2. Complete response rate

    Complete response rate is defined as the percentage of patients treated achieving a complete response (CR) as assessed according to the Global Response Criteria for CTCL and and International Consensus Criteria for T-LGLL.

    Time frame: Through completion of treatment (estimated to be 12 months)

  3. Duration of response

    Duration of response is defined as the time from first initial response to progression of disease as assessed according to the Global Response Criteria for CTCL and and International Consensus Criteria for T-LGLL.

    Time frame: From date of first response through disease progression (estimated to be 22 months)

  4. Time to maximum response

    Time to maximum response is defined by the time from initiation of study therapy to the time to achieve the best response as assessed according to the Global Response Criteria for CTCL and and International Consensus Criteria for T-LGLL.

    Time frame: Through completion of treatment (estimated to be 12 months)

  5. Clinical benefit rate

    Clinical benefit rate is defined by the percentage of patients treated who have achieved a complete response (CR), partial response (PR) or have stable disease (SD) for 6 months or greater as assessed according to the Global Response Criteria for CTCL and and International Consensus Criteria for T-LGLL.

    Time frame: Through completion of treatment (estimated to be 12 months)

  6. Frequency and grades of treatment-emergent adverse events (TEAE)

    As assessed by CTCAE v6.0

    Time frame: From start of treatment through start of new treatment or 30 days after completion of treatment, whichever is earlier (estimated to be 13 months)

  7. Rate of treatment discontinuation due to TEAE

    As assessed by CTCAE v6.0

    Time frame: Through completion of treatment (estimated to be 12 months)

07

Study locations

1 site
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    • Neha Mehta-Shah, MD · Contactmehta-n@wustl.edu · 557-747-2108
    • Neha Mehta-Shah, MD · Principal investigator
    • Hunter C Cochran, MD · Sub investigator
    • Todd Fehniger, MD, PhD · Sub investigator
    • Jacqueline Payton, MD, PhD · Sub investigator
    • Fei Wan, PhD · Sub investigator
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2030, 39 months later.

Of 33 non-industry phase 2 interventional studies under Mycosis Fungoides, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 119. This study's planned 39 months is below that.

Counting every sponsor, half of 42 studies reached it within 64 months; a quarter within 39 and three quarters within 111.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Sep 2026 → Dec 2026, primary completion Jan 2030 → Apr 2030 and completion Sep 2032 → Dec 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 6, 2026
StartEst.
Dec 31, 2026was Sep 2026
Primary completionEst.
Apr 30, 2030was Jan 2030
CompletionEst.
Dec 31, 2032was Sep 2032
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 30, 2026→Dec 31, 2026
Nov 5, 2026
Primary completion
Jan 31, 2030→Apr 30, 2030
Nov 5, 2026
Study completion
Sep 30, 2032→Dec 31, 2032
Nov 5, 2026
Eligibility
8 criteria edited, 27 added, 4 removed
What changed in the criteria
  • EditedHistologically or cytologically confirmed mycosis fungoides or Sézary syndrome, stages IB to IVB with measurable disease and/or detectable blood involvement based on the Global Response Criteria for CTCL (Olsen et al., 2022).
  • AddedRequires systemic therapy for their CTCL, in the opinion of the treating physician.
  • RemovedSerum Creatinine ≤ 2 x IULN
  • RemovedEstimated glomerular filtration rate (eGFR) ≥ 30 mL/min using the Modification of Diet in Renal Disease (MDRD) equation (multiplying eGFR by each subject's Body Surface Area [BSA])
  • AddedEstimated (as calculated by the Cockcroft-Gault method) or measured creatinine clearance ≥ 30 mL/min.
  • EditedPatients must be ableAble to swallow pills.
  • Edited-Diagnosis of T-LGLL defined as: CD3+CD8+ cell population > 650/mm3 or CD3+CD8+CD57+ population > 500/mm3 and the presence of a clonal T-cell receptor (within 1 month of diagnosis).
  • EditedUntreated T-LGLL or failedHad at least one line of frontlinesystemic therapy for T-LGLL.
  • EditedPatients must requireRequire treatment for T-LGLL, as defined by meeting one or more of the below criteria:
  • RemovedSerum Creatinine ≤ 2 x IULN
  • RemovedEstimated glomerular filtration rate (eGFR) ≥ 30 mL/min using the Modification of Diet in Renal Disease (MDRD) equation (multiplying eGFR by each subject's Body Surface Area [BSA])
  • AddedEstimated (as calculated by the Cockcroft-Gault method) or measured creatinine clearance ≥ 30 mL/min.
  • EditedPatients must be ableAble to swallow pills.
  • EditedPatients with activeActive CNS lymphoma.
  • AddedReceipt of medications or herbal supplements known to be strong inhibitors of CYP3A4 within the following time frames prior to the first dose of golidocitinib:
  • Added7 days for Ketoconazole, itraconazole, indinavir, saquinovir, nelfinavir, atazanavir, amprenavir, fosamprenavir, troleandomycin, telithromycin, fluconazole, nefazodone, cimetidine, aprepitant, miconazole, fluvoxamine
  • Added14 days for Erythromycin, clarithromycin, verapamil, ritonavir, diltiazem
  • Added6 weeks for amiodarone
  • AddedReceipt of medications known to prolong the QT interval within the following time frames:
  • Added2 days for clarithromycin, droperidol, erythromycin, procainamide
  • Added14 days for Cisapride, disopyramide, dofetilide, domperidone, ibutilide, quinidine, sotalol, sparfloxacin, thioridazine
  • Added4 weeks for levomethadyl, methadone, pimozide
  • Added6 weeks for arsenic trioxide
  • Added8 weeks for pentamidine
  • Added52 weeks for chloroquine
  • AddedQTcF ≥ 480 msec.
  • EditedPatients with activeActive CNS involvement with T-LGLL.
  • AddedReceipt of medications or herbal supplements known to be strong inhibitors or inducers of CYP3A4 within the following time frames prior to the first dose of golidocitinib:
  • Added7 days for Ketoconazole, itraconazole, indinavir, saquinovir, nelfinavir, atazanavir, amprenavir, fosamprenavir, troleandomycin, telithromycin, fluconazole, nefazodone, cimetidine, aprepitant, miconazole, fluvoxamine
  • Added14 days for Erythromycin, clarithromycin, verapamil, ritonavir, diltiazem
  • Added6 weeks for amiodarone
  • AddedReceipt of medications known to prolong the QT interval within the following time frames:
  • Added2 days for clarithromycin, droperidol, erythromycin, procainamide
  • Added14 days for Cisapride, disopyramide, dofetilide, domperidone, ibutilide, quinidine, sotalol, sparfloxacin, thioridazine
  • Added4 weeks for levomethadyl, methadone, pimozide
  • Added6 weeks for arsenic trioxide
  • Added8 weeks for pentamidine
  • Added52 weeks for chloroquine
  • AddedQTcF ≥ 480 msec.
Nov 5, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionOverall Response Rate (ORR): how it is measured was reworded
Nov 5, 2026
Secondary outcomes
5 description edited
What changed in the outcomes
  • DescriptionBest overall response rate: how it is measured was reworded
  • DescriptionClinical benefit rate: how it is measured was reworded
  • DescriptionComplete response rate: how it is measured was reworded
  • DescriptionDuration of response: how it is measured was reworded
  • DescriptionTime to maximum response: how it is measured was reworded
Nov 5, 2026
Sponsor
Collaborators added: Swim Across America
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Start date Sep 30, 2026→Dec 31, 2026
    Primary completion Jan 31, 2030→Apr 30, 2030
    Study completion Sep 30, 2032→Dec 31, 2032
    Eligibility 8 criteria edited, 27 added, 4 removed
    What changed in the criteria
    • EditedHistologically or cytologically confirmed mycosis fungoides or Sézary syndrome, stages IB to IVB with measurable disease and/or detectable blood involvement based on the Global Response Criteria for CTCL (Olsen et al., 2022).
    • AddedRequires systemic therapy for their CTCL, in the opinion of the treating physician.
    • RemovedSerum Creatinine ≤ 2 x IULN
    • RemovedEstimated glomerular filtration rate (eGFR) ≥ 30 mL/min using the Modification of Diet in Renal Disease (MDRD) equation (multiplying eGFR by each subject's Body Surface Area [BSA])
    • AddedEstimated (as calculated by the Cockcroft-Gault method) or measured creatinine clearance ≥ 30 mL/min.
    • EditedPatients must be ableAble to swallow pills.
    • Edited-Diagnosis of T-LGLL defined as: CD3+CD8+ cell population > 650/mm3 or CD3+CD8+CD57+ population > 500/mm3 and the presence of a clonal T-cell receptor (within 1 month of diagnosis).
    • EditedUntreated T-LGLL or failedHad at least one line of frontlinesystemic therapy for T-LGLL.
    • EditedPatients must requireRequire treatment for T-LGLL, as defined by meeting one or more of the below criteria:
    • RemovedSerum Creatinine ≤ 2 x IULN
    • RemovedEstimated glomerular filtration rate (eGFR) ≥ 30 mL/min using the Modification of Diet in Renal Disease (MDRD) equation (multiplying eGFR by each subject's Body Surface Area [BSA])
    • AddedEstimated (as calculated by the Cockcroft-Gault method) or measured creatinine clearance ≥ 30 mL/min.
    • EditedPatients must be ableAble to swallow pills.
    • EditedPatients with activeActive CNS lymphoma.
    • AddedReceipt of medications or herbal supplements known to be strong inhibitors of CYP3A4 within the following time frames prior to the first dose of golidocitinib:
    • Added7 days for Ketoconazole, itraconazole, indinavir, saquinovir, nelfinavir, atazanavir, amprenavir, fosamprenavir, troleandomycin, telithromycin, fluconazole, nefazodone, cimetidine, aprepitant, miconazole, fluvoxamine
    • Added14 days for Erythromycin, clarithromycin, verapamil, ritonavir, diltiazem
    • Added6 weeks for amiodarone
    • AddedReceipt of medications known to prolong the QT interval within the following time frames:
    • Added2 days for clarithromycin, droperidol, erythromycin, procainamide
    • Added14 days for Cisapride, disopyramide, dofetilide, domperidone, ibutilide, quinidine, sotalol, sparfloxacin, thioridazine
    • Added4 weeks for levomethadyl, methadone, pimozide
    • Added6 weeks for arsenic trioxide
    • Added8 weeks for pentamidine
    • Added52 weeks for chloroquine
    • AddedQTcF ≥ 480 msec.
    • EditedPatients with activeActive CNS involvement with T-LGLL.
    • AddedReceipt of medications or herbal supplements known to be strong inhibitors or inducers of CYP3A4 within the following time frames prior to the first dose of golidocitinib:
    • Added7 days for Ketoconazole, itraconazole, indinavir, saquinovir, nelfinavir, atazanavir, amprenavir, fosamprenavir, troleandomycin, telithromycin, fluconazole, nefazodone, cimetidine, aprepitant, miconazole, fluvoxamine
    • Added14 days for Erythromycin, clarithromycin, verapamil, ritonavir, diltiazem
    • Added6 weeks for amiodarone
    • AddedReceipt of medications known to prolong the QT interval within the following time frames:
    • Added2 days for clarithromycin, droperidol, erythromycin, procainamide
    • Added14 days for Cisapride, disopyramide, dofetilide, domperidone, ibutilide, quinidine, sotalol, sparfloxacin, thioridazine
    • Added4 weeks for levomethadyl, methadone, pimozide
    • Added6 weeks for arsenic trioxide
    • Added8 weeks for pentamidine
    • Added52 weeks for chloroquine
    • AddedQTcF ≥ 480 msec.
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionOverall Response Rate (ORR): how it is measured was reworded
    Secondary outcomes 5 description edited
    What changed in the outcomes
    • DescriptionBest overall response rate: how it is measured was reworded
    • DescriptionClinical benefit rate: how it is measured was reworded
    • DescriptionComplete response rate: how it is measured was reworded
    • DescriptionDuration of response: how it is measured was reworded
    • DescriptionTime to maximum response: how it is measured was reworded
    Sponsor Collaborators added: Swim Across America
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07682792
Collaborators
Dizal Pharmaceuticals, Swim Across America
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Dec 31, 2026 (estimated)
Primary completion
Apr 30, 2030 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Nov 5, 2026

Study contacts

Neha Mehta-Shah, MD
Contact
mehta-n@wustl.edu
557-747-2108
Neha Mehta-Shah, MD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golidocitinib

Start the discussion